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Abstract 
 
Background: Identification of individuals at high risk of heart failure and early risk factor 
modification with medications such as ACE inhibitors may delay the onset of heart failure. High-
sensitivity cardiac troponin (hs-cTn) has been suggested as a prognostic marker for the incidence of 
first-ever heart failure in asymptomatic individuals. 
 
Methods: Pubmed, Embase and Web of Science were systematically searched for prospective 
cohort studies published before January 2017 that reported associations between hs-cTn and 
incident heart failure in individuals without baseline heart failure. Study-specific multivariable 
adjusted hazard ratios were pooled using random-effects meta-analysis.  
 
Results: Data were collated from sixteen studies with a total of 67,063 individuals and 4,165 
incident heart failure events. Average age was 57 years and 47% were female. Study quality was 
high (Newcastle-Ottawa score: 8.2/9). In a comparison of participants in the top third with those in 
the bottom third of baseline values of hs-cTn, the pooled multivariable adjusted hazard ratio for 
incident heart failure was 2.09 (95% CI 1.76-2.48, p<0.001). Between-study heterogeneity was high 
with an I
2
 of 80%. Hazard ratios were similar in men and women (2.29 [1.64-3.21] vs 2.18 [1.68-
2.81]), with hs-cTnI and hs-cTnT (2.09 [1.53-2.85] vs 2.11 [1.69-2.63]) and across other study-level 
characteristics. Further adjustment for B-type natriuretic peptides yielded a similar hazard ratio of 
2.08 (1.64-2.65). Assay of hs-cTn in addition to conventional risk factors provided improvements in 
the c-index of 1-3%. 
 
Conclusions: Available prospective studies indicate a strong association of hs-cTn with the risk of 
first-ever heart failure and significant improvements in heart failure prediction.  
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Introduction 
Cardiac troponins are structural proteins in the contractile apparatus of the myocyte. 
Upon myocardial damage, they are released into the circulation (1) and they are 
therefore central in the diagnosis of myocardial infarction (2). Measurement of cardiac 
troponin with early assays was considered as a dichotomous test, classifying patients as 
being positive or negative for myocardial infarction. The advent of high-sensitivity 
cardiac troponin (hs-cTn) assays in recent years has changed this paradigm. High-
sensitivity assays have allowed cardiac troponin to be considered as a quantitative 
measure of cardiac myocyte injury in the setting of myocardial infarction, and can 
measure cardiac troponin at low concentrations in individuals without myocardial 
infarction, where it can be regarded as a marker for myocardial stress (2,3).  
 
We have previously demonstrated in a meta-analysis of 29 studies that cardiac troponin 
concentration in people without manifest cardiovascular disease (CVD) is associated 
with the long-term risk of developing coronary heart disease or stroke (4). In addition to 
these two outcomes, hs-cTn may also be a prognostic marker for the development of 
heart failure (HF). Identification of better prognostic marker for incident HF is important 
because HF is associated with poor survival, reduced quality of life, and significant 
healthcare costs (5). Furthermore, as reported by a recent UK-based study, HF has 
become the most common initial presentation of CVD (6). Still, prediction models 
aiming to identify individuals at high risk of HF are currently not included in CVD 
prevention guidelines (7,8) and are not established in clinical practice (9). The potential 
of cardiac biomarkers in HF prediction is exemplified by a meta-analysis showing 
natriuretic peptides improve risk discrimination and classification in general population 
studies (10). Risk scores for HF could help target preventive medication, such as statins 
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(11), intensive blood pressure control (12), and angiotensin-converting-enzyme 
inhibitors (13).  
 
The aim of this study was to systematically collate and appraise the available evidence 
regarding the association between hs-cTn and incident HF and the added value of hs-cTn 
in HF prediction. 
 
Methods 
This systematic review is reported in accordance with the Meta-Analysis of 
Observational Studies in Epidemiology (MOOSE) guideline (14) and the protocol was 
registered prospectively with PROSPERO (CRD42017054828). 
 
Literature search 
Electronic searches of Pubmed, Embase and Web of Science were performed on 3rd 
January 2017 (search strategy detailed in Supplementary table 1) with no filters or 
language restrictions applied. This was supplemented by review of relevant conference 
proceedings (i.e. American Heart Association Scientific Sessions, American College of 
Cardiology Sessions, European Society of Cardiology Annual Congress from 2014-
2016) and of reference lists of identified studies. The searches were conducted by two 
independent investigators (J.E. and S.D.) and any discrepancies were resolved, by 
consensus, with a third investigator (S.P.). 
 
Study eligibility criteria 
To be eligible for inclusion, studies were required to: (i) have a prospective study design, 
including studies nested in randomized controlled trials; (ii) have enrolled individuals 
without HF at baseline; (iii) had measured high-sensitivity cardiac troponin; and (iv) had 
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recorded incident HF events over at least 1 year. Studies were excluded which involved 
patients in the early phase after acute myocardial infarction, undergoing cardiotoxic 
chemotherapy or with established myocardial or multisystem disease (e.g. sarcoidosis, 
amyloidosis).  
 
Data extraction 
Using a pre-specified data collection sheet, data were collated on population type 
(general vs high-risk populations), mean age, sex, ethnicity, baseline history of 
hypertension, diabetes, and CVD, hs-cTn assay type and manufacturer, number of 
participants, duration of follow-up and number of incident HF events. Furthermore, we 
assessed quality of included studies using the Newcastle-Ottawa tool for cohort studies 
(15), which considers participant selection, exposure measurement, ascertainment of 
outcomes, covariate adjustment, and adequacy of follow up. We also recorded which 
methods studies used to record incident HF events and how they defined them (fatal, 
non-fatal, or both). Hazard ratios for the association between hs-cTn and incident HF 
were extracted with the following levels of covariate adjustment, where available: (1) 
unadjusted or adjusted only for age and sex, (2) adjusted for demographic factors, 
conventional CVD risk factors and/or biomarkers other than natriuretic peptides, (3) 
adjusted for demographic factors, conventional CVD risk factors, non-natriuretic peptide 
biomarkers and natriuretic peptide levels. Where reported, C-indices as a measure for 
risk discrimination were extracted for predictive models with and without hs-cTn 
assessment.  
 
Statistical analysis 
All statistical analyses were performed using Stata Version 13 (StataCorp, USA) and a 
2-sided p-value of <0.05 was deemed to represent statistical significance in the primary 
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analysis and <0.01 in meta-regression analyses due to multiple testing. Studies reported 
hazard ratios in different ways. These included a hazard ratio describing those above and 
below a specific threshold, between top and bottom quartiles or quintiles, per unit 
increase or per standard deviation increase in hs-cTn. In order to allow direct comparison 
of study specific hazard ratios, hazard ratios were transformed to represent the hazard 
ratio for the top third versus the bottom third of hs-cTn concentration within a given 
study. This transformation was performed under the assumption that the exposure 
variable is normally distributed and a log-linear association between exposure and 
outcome, as previously described (16,17). When estimates were presented both by 
groups of cardiac troponin as a categorical variable and as a continuous measure, the 
continuous measure was used as this is more compatible with the linear assumption used 
when transforming hazard ratios. 
 
For the primary analysis, the most adjusted study-specific hazard ratios for the 
association between hs-cTn and incident HF were pooled by random effects inverse-
variance weighted meta-analysis using the method of DerSimonian and Laird (18). This 
random-effects method was selected a priori due to a degree of anticipated heterogeneity 
in the populations studied and the design of included studies. Between-study 
heterogeneity was quantified using the I
2
 statistic (19).  
 
Secondary analyses pooled sex-specific hazard ratios using data from studies that 
reported associations separately in both men and women and compared hazard ratios 
according to the three pre-specified levels of covariate adjustment. Furthermore, meta-
regression was used to test whether associations differed according to study-level 
characteristics. For categorical study-level characteristics, pooled hazard ratios were 
calculated within each subgroup. For continuous variables, study-specific estimates of 
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the association between hs-cTn and HF were plotted against the value of the variable of 
interest and a regression line fitted. The presence of publication bias was assessed with 
funnel plots and Egger’s test (20).  
Results 
Summary of included studies 
Electronic searches yielded 2,982 unique citations (Figure 1). Shortly after the date of 
the electronic searches, full text manuscripts of two abstracts identified in the search 
process were published and included (21,22). Data from 16 unique studies (21-35), 
reporting data regarding 67,063 participants with 4,165 first HF events, were included in 
this review. The included studies are summarized in Table 2. Ten studies included a 
sample of the general population and six comprised high-risk populations with either 
stable CVD, type II diabetes, chronic kidney disease or hypertension. All were 
prospective cohort studies; four were nested within randomized controlled trials. Seven 
studies were conducted in North America, five in Western Europe, two in East Asia, and 
two across multiple continents. All studies excluded individuals with a diagnosis of HF 
at baseline. Okuyama et al additionally excluded individuals with a left ventricular 
ejection fraction <50%; McQueen et al and Omland et al excluded those known to have 
a left ventricular ejection fraction <40%. Eight studies used HF hospitalization alone as 
the endpoint, four used all fatal or non-fatal HF diagnoses/events and two reported all 
non-fatal HF diagnoses/events.  Overall, the quality of the included studies was good. 
Three studies fulfilled all nine elements of the Newcastle-Ottawa score, with the other 13 
fulfilling eight of the nine criteria. The individual elements and overall Newcastle-
Ottawa scores are shown in Supplementary Table 5. More detailed descriptions of the 
study population, method of follow up, outcome definitions, covariate adjustment and 
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details of the cardiac troponin assays used are reported in the appendix (Supplementary 
Tables 2-4).  
 
Association of high-sensitivity cardiac troponin with incident HF 
The pooled hazard ratio for incident HF comparing individuals in the top third versus 
those in the bottom third of hs-cTn concentration was 2.09 (95% confidence interval: 
1.76-2.48, p<0.0001, Figure 2). There was evidence of significant heterogeneity with an 
I
2
 (95% CI) of 80 (68-87) %. The pooled hazard ratio was not materially changed upon 
further adjustment for B-type natriuretic peptide levels on top of CVD risk factors 
(Figure 3).  
 
Sensitivity analysis using meta-regression confirmed that none of the categorical or 
continuous study level variables assessed were associated with differences in the hazard 
ratio for the association between hs-cTn and incident HF (Figure 4 and Supplementary 
Figure 2). Pooled hazard ratios were 2.29 (1.64-3.21) in men, 2.18 (1.68-2.81) in 
women, 2.09 (1.53-2.85) with hs-cTnI, and 2.11 (1.69-2.63) with hs-cTnT. There was 
some evidence for publication bias on inspection of the funnel plot with two smaller 
studies reporting hazard ratios greater than the pooled estimate (Supplementary Figure 
3), but the Egger’s test was non-significant (p=0.126). 
 
Association of high-sensitivity cardiac troponin with heart failure subtypes 
Two studies reported associations between hs-cTn and heart failure with preserved 
(HFpEF) and reduced ejection fraction (HFrEF) separately. In the PREVEND study, the 
hazard ratio for those with hs-cTnT in the top versus bottom third was greater for HFrEF 
(HR 1.79 (1.55-2.07)) than HFpEF (HR 1.30 (1.07-1.50)) (24). In the Cardiovascular 
Health Study, in those without left ventricular hypertrophy by echocardiography at 
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baseline, the corresponding hazard ratios were 2.70 (1.64-4.40) for HFrEF and 1.85 
(1.30-2.68) for HFpEF (36). No studies reported data regarding heart failure with mid-
range ejection fraction. 
 
 
Association of changes in hs-cTn and incident heart failure 
Two studies reported the association between changes in hs-cTn over time and incident 
heart failure. In the Cardiovascular Health Study, in those with a detectable hs-cTnT at 
baseline, the hazard ratio associated with a >50% increase 2-3 years later was 1.61 (1.32-
1.97) after adjusting for conventional CVD risk factors. In the Atherosclerosis Risk in 
Communities Study, the corresponding hazard ratio for a >50% change in hs-cTnT at six 
years was 1.64 (1.39-1.95) (37). In those with undetectable hs-cTnT (<5ng/L) at 
baseline, a detectable value (>5ng/L) at six years was associated with a hazard ratio of 
1.96 (1.62-2.37) (37). 
 
Incremental discrimination with addition of hs-cardiac troponin 
Eight studies reported improvements in the c-index upon assessment of hs-cTn in 
addition to assessment of conventional CVD risk factors. Reported findings generally 
demonstrated improvements in risk discrimination, with c-index changes in the region of 
0.01 to 0.03 with the additional assessment of hs-cTn (Figure 5). Because some studies 
did not report confidence intervals for c-indices and their changes, it was not possible to 
conduct a quantitative meta-analysis of the c-index data. 
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Discussion 
This systematic review and meta-analysis involving data from 16 prospective studies 
demonstrates a strong association between hs-cTn and the development of incident HF. 
The data suggest that individuals with a hs-cTn value in the top third of the population 
have a greater than two-fold increased risk of developing HF compared with individuals 
in the bottom third. This association was independent of conventional cardiovascular risk 
factors and natriuretic peptide levels, and consistent in the general population and high-
risk groups, and in men and women. Assessment of hs-cTn in addition to conventional 
CVD risk factors improved risk discrimination quantified with the c-index, with study-
specific estimates between 0.01 and 0.03. These data suggest that measurement of hs-
cTn may enhance the ability to identify individuals at greater risk of developing HF.  
Hs-cTn troponin may be useful as a means of targeting echocardiographic screening for 
HF in high risk individuals to identify asymptomatic left ventricular dysfunction and 
allow early treatment (13), as has been studied for natriuretic peptides (38), although 
such an approach would require further evaluation. 
 
Hs-cardiac troponin assays have been used in clinical practice in the diagnosis of 
myocardial infarction for some time and have recently been approved by the FDA for 
use in the United States (39). Elevated circulating cardiac troponin has been associated 
with worse clinical outcome in patients with acute decompensated HF (40) and chronic 
stable HF (41). The mechanisms triggering the release of circulating cardiac troponin in 
people without clinically manifest myocardial ischemia is unclear. It is speculated that 
contributing factors are underlying coronary artery disease, subendocardial ischemia, 
increased wall stress or left ventricular hypertrophy (25). Another possible mechanism is 
the cardiac stress characterized by activation of the renin-angiotensin and adrenergic 
systems, which has been studied in detail in patients with HF (42).  
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The studies contributing to our meta-analysis excluded individuals with symptomatic HF 
or a previous diagnosis of HF at baseline. However, some of them enrolled individuals 
with subclinical myocardial dysfunction at baseline, which tend to have a higher level of 
hs-cTn.  Among participants with hs-cTnT (>8.8 ng/L) in the Multi-Ethnic Study of 
Atherosclerosis, 8.4% of men and 4.3% of women had a left ventricular ejection fraction 
<50%, and 18.2% of men and 27.7% of women had left ventricular hypertrophy assessed 
with cardiac magnetic resonance imaging (21). In the PEACE study involving patients 
with stable coronary heart disease, the prevalence of left ventricular ejection fraction 
between 40-50% was 14.4% in the whole cohort, increasing from 11.4% to 18.4% in the 
lowest to highest quartile of hs-cTnT (31). It should however be noted that the 
association of hs-cTn and incident HF was observed even after exclusion of individuals 
with left ventricular hypertrophy in the Cardiovascular Health Study (36).  
 
Natriuretic peptides are the best-studied biomarkers in HF and strong predictors of 
prognosis in patients with established HF (43). A recent individual participant data meta-
analysis of the association between natriuretic peptide levels and incident HF in the 
general population reported a risk ratio for individuals the top third versus the bottom 
third of 3.45 (2.66-4.46) (10). The magnitude of this association for natriuretic peptide is 
greater than that observed in our meta-analysis for hs-cTn, however those studies had not 
adjusted for hs-cTn. While individuals with hs-cTn tend to have higher natriuretic 
peptide levels (21,25,31), the magnitude of the Spearman correlation co-efficient was 
modest at 0.36 in the Cardiovascular Health Study (25). In studies that adjusted for 
natriuretic peptide in our analysis, the pooled hazard ratio was 2.08 (1.64-2.65), only a 
slight attenuation of the association without adjustment for natriuretic peptides of 2.39 
(1.99-2.87). This suggests that hs-cTn has a strong association with incident HF 
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independent of natriuretic peptide levels. A literature based meta-analysis of 29 studies 
examining the association between hs-cTn and coronary heart disease and stroke 
reported risk ratios for the top versus bottom third of 1.59 (95% CI 1.38-1.83) for CHD 
and 1.35 (95% CI 1.23-1.48) for stroke (4). Thus the association between hs-cTn and HF 
is stronger than that for either CHD or stroke, a similar trend to that observed for NT-
proBNP (10). With regards to improvement in risk discrimination, the C-index change 
with additional assessment of hs-cTn was lower than that previously observed for 
natriuretic peptides (0.01-0.03 vs 0.038) (10).  
 
It has to be noted that the studies included in our meta-analysis relied on a single 
measurement of hs-cTn, whereas repeat measurements are likely to be more informative. 
In the Cardiovascular Health Study, in individuals with an elevated baseline hs-cTn, 
those with a further increase at follow-up had a higher HF risk compared with those with 
no change or a decrease in hs-cTn (25). This observation is in line with similar data from 
the ARIC study (37), suggesting that serial measurements of biomarkers may provide 
additional information over a single measurement. After developing a biomarker score 
based on concentrations of five biomarkers, including hs-cTn, investigators from the 
Framingham Heart Study observed a greater than 6-fold increase in the risk of HF in 
those with a score in the top quintile versus the bottom quintile (34). This score also 
improved discrimination and reclassification in terms of HF risk. Serial testing of 
biomarkers including hs-cTn and the use of multiple biomarkers simultaneously appears 
to hold promise, but is inevitably more resource intensive and costly. 
 
Strengths and limitations 
This systematic review has pooled data from sixteen studies reporting data from 67,063 
participants with 4,165 HF events, giving significant statistical power. This study adds to 
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the existing literature in this field by providing an overview of all the available evidence 
regarding the association between hs-cTn and heart failure, with particular strengths 
including the thorough and comprehensive search strategy, transformation of study 
specific hazard ratios to a common scale to allow comparison and the high 
methodological quality of the included studies. There are however a number of 
limitations that merit discussion. There was significant heterogeneity observed in our 
analyses. No single factor was clearly demonstrated to account for a large proportion of 
this heterogeneity in meta-regression analyses and it is likely to be multifactorial. The 
assumption of a normally distributed exposure variable and a linear association with the 
outcome of interest may have been violated in some studies where individuals were 
categorized based on hs-cTn levels. A non-linear relationship could lead to an inflated 
hazard ratio after transformation, however there was no significant interaction between 
estimates from studies who modeled hs-cTn as a continuous or categorical variable. 
Finally, incomplete reporting of confidence intervals for C-index values prevented 
quantitative synthesis of this data and this element is descriptive only. 
 
Given the potential for both clinical and methodological sources of heterogeneity in the 
included studies, collating individual-patient-level data from all of these studies would 
be valuable. This would allow standardization of outcome definitions and covariate 
adjustment. It would also allow for analysis of associations and assessment for effect 
modification in important subgroups and standardized assessment of the effect of adding 
hs-cTn to HF risk prediction models in terms of discrimination and calibration. 
 
Summary 
Serum hs-cTn is associated with the risk of incidence HF. The association equally 
applied to the general population and high-risk populations, and was independent of 
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conventional CVD risk factors and natriuretic peptide levels. Preliminary data showing 
discrimination improvements in HF risk with hs-cTn assessment suggest it may be a 
promising biomarker for measurement as part of primary prevention of HF. 
 
 
Clinical perspective 
 
People with higher levels of circulating cardiac troponin are at higher risk of developing 
new onset heart failure, after accounting for conventional risk factors and natriuretic 
peptide levels. Measurement of high sensitivity cardiac troponin improves the 
discrimination of heart failure risk. High sensitivity cardiac troponin may be useful in 
identifying individuals at high risk of heart failure to target preventive interventions. 
 
Translational outlook 
 
An individual-participant-data meta-analysis would help clarify the added value of high 
sensitivity cardiac troponin in the prediction of new onset heart failure, beyond 
conventional risk factors. 
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Figure legends 
 
Figure 1.  
Search results and study selection process 
 
Figure 2.  
Forest plot for primary analysis of maximally adjusted hazard ratios for the association 
between hs-cTn and incident heart failure.  
 
Heterogeneity: I
2
 = 79.9% (95% CI - 68.1 - 87.3%). Abbreviations: NR=not reported, 
HR=hazard ratio. Level of adjustment: ‘++’= adjusted for demographics and CVD risk 
factors, ‘+++’= adjusted for demographics, CVD risk factors and natriuretic peptides. 
 
Figure 3.  
Hazard ratios for association between hs-cTn and incident heart failure by the degree of 
covariate adjustment. 
 
Studies contribute to multiple levels if hazard ratios are reported at each level of 
adjustment. Abbreviations: NPs=natriuretic peptides (NT-proBNP or BNP), 
CVD=Cardiovascular disease. Comparisons are indirect as not all studies were included 
in analyses at each level of covariate adjustment. 
 
Figure 4.  
Meta-regression by categorical study level characteristics 
 
**Manner in which hazard ratios were reported in original paper. * P-value calculated 
using meta-regression. Abbreviations – RCT=randomized controlled trial. 
 
Figure 5.  
Change in C-index with addition of hs-cTn by study 
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Table 1. Summary of included prospective cohort studies and baseline characteristics of participants 
 
Study author Study Type of Study 
Population 
Mean age 
(years) 
Female 
(%) 
Race  
(% White) 
Hypertension 
(%) 
Diabetes 
(%) 
CVD (%) Troponin  
assay 
Follow up 
(years) 
Participants 
(number) 
HF events 
(number) 
Outcome 
definition 
Follow up 
method 
 General population              
Brouwers 2014 PREVEND General population 49 50 96 14 1 7 hsTnT (Roche) 13* 8569 374 All RL& 
De Filipi 2010 CHS General population 73 60 NR 60 18 18 hsTnT(Roche) 12* 4221 1279 NF SR, RL& 
Eggers 2016 PIVUS General population 70 50 NR 70 11 0 hsTnI (Abbott) 10^ 864 67 All RL 
Ford 2016 WOSCOPS General populationa 55 0 NR 16 1 5 hsTnI (Abbott) 15^ 3318 61 Hosp. RL 
Lyngbakken 2016 HUNT2 General population 47* 56 100 41 2 0 hsTnI (Abbott) 17* 9114 209 Hosp. RL 
McKie 2014 REP General population 62 52 NR 28 7 12 hsTnT (Siemens) 11* 1843 193 All RL 
Neumann 2014 FINRISK General population 48 50 100 45 5 0 hsTnI (Singulex) 14^ 7899 505 NR RL 
Saunders 2011 ARIC General population 63 59 78 45 15 0 hsTnT (Roche) 10* 9276 665 Hosp. RL 
Seliger 2017 MESA General population 62 57 39 42 11 0 hsTnT (Roche) 12* 4986 177 Hosp. SR& 
Wang 2012 FHS General population 59 53 NR 28 12 5 hsTnI (Singulex) 11$ 3428 149 NF RL& 
  High risk groups              
Bansal 2014 CRIC CKD 58 46 43 NR 46 26 hsTnT (Roche) 6* 3483 320 Hosp. SR, RL& 
McQueen 2013 HOPE High riska 65 23 NR 42 35 94 hsTnT (Roche) 5$ 2941 NR All Trial& 
Okuyama 2017 Fujita  Hypertensive 69 29 0 100 43 20 hsTnI (Abbott) 7.2$ 493 44 Hosp. SR, RL 
Omland 2009 PEACE Stable CVDa 64 19 92 45 16 100 hsTnT (Roche) 5* 3679 104 Hosp, F Trial 
Scirica 2016 SAVOUR-TIMI-53 Diabetesa 65 33 80 82 100 0 hsTnT (Roche) 2* 2673 NR Hosp. Trial 
Yiu 2014 CDATS Diabetes 64 44 0 70 100 29 hsTnI (Abbott) 5* 276 18 Hosp. SR, RL 
Total   57 47 82 40 16 14  11 67,063 4,165   
 
*Median ^maximum $mean anested in RCT.Abbreviations: NR=not reported, All=Fatal and non-fatal heart failure including hospitalization, NF=non-fatal heart failure, Hosp.=hospitalization for 
heart failure, F=fatal heart failure, RL=record linkage/medical record review, SR=self-report, Trial=active follow up within trial, &=endpoint adjudication performed, CKD=chronic kidney disease, 
CVD=cardiovascular disease, hsTnT=high sensitivity troponin T, hsTnI=high sensitivity troponin I. Full study names: PREVEND=Prevention of Vascular and Renal Endstage Disease, 
CHS=Cardiovascular Health Study, PIVUS=Prospective Investigation of the Vasculature in Uppsala Seniors study, WOSCOPS=West of Scotland Coronary Prevention Study, HUNT2=Nord-
Trondelag Health Study, REP=Rochester Epidemiology Project, FINRISK=FINRISK study, ARIC=Atherosclerosis Risk in Communities, MESA=Multi-ethnic Study of Atherosclerosis, 
FHS=Framingham Heart Study, CRIC=Chronic Renal Insufficiency Cohort, HOPE=Heart Outcomes Prevention Evaluation, PEACE=Prevention of events with angiotensin converting enzyme 
inhibition trial, SAVOUR-TIMI-53=Saxagliptin Assessment of Vascular Outcomes Recorded with Diabetes Mellitus study, CDATS=Chinese Diabetic Heart Study.
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